[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 13, Issue 3 (Summer 2022) ::
Caspian J Intern Med 2022, 13(3): 617-622 Back to browse issues page
Efficacy of levetiracetam, lamotrigine and sodium valproate on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy: A double blind randomized clinical trial
Sajjad Daneshyar , Masoud Ghiasian * , Sahar Moradi , Elham Khanlarzadeh
Department of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran , Masoud_ghiasian@yahoo.com
Abstract:   (235 Views)
Background: Juvenile myoclonic epilepsy (JME) is one of the most important types of generalized idiopathic epilepsy. Patients generally respond quickly and perfectly to standard antiepileptic drugs but lifelong medication is necessary. Sodium valproate is the drug of choice in most references but it has some adverse reactions and some patients cannot tolerate the complications. Because of the need for life long treatment in this young aged group particularly child bearing women, we aimed to analyze the efficacy of these drugs to determine which has better efficacy with lower adverse effects.
Methods: In this double-blind clinical trial 102 patients suffering from juvenile myoclonic epilepsy were randomly divided to three groups and treated with valproate, levetiracetam or lamotrigine and followed for 12 months at specified intervals.
Results: Patients' mean age was 22.8 years and 28.4% of them were males and 71.6% were females. Effective terminal dose of sodium valproate, levetiracetam and lamotrigine were 1000, 1000 and 250mg, respectively. The rate of failure in controlling seizures and myoclonic jerks in lamotrigine group was meaningfully more than levetiracetam and sodium valproate (P=0.037).The general side effects of sodium valproate were much more; but there was not any significant difference between their effects on electroencephalogram (EEG) findings (P=0.81).
Conclusion: Levetiracetam and sodium valproate have similar efficacy. But in the group of lamotrigine, rate of failure, myoclonus and drug adverse reactions were meaningfully more than sodium valproate and levetiracetam. According to our study, lamotrigine could not be a suitable treatment option for JME patients as a mono therapy. Levetiracetam can be a good alternative to sodium valproate, especially in women of childbearing age
Keywords: Sodium valproate, levetiracetam, lamotrigine, juvenile myoclonicepilepsy
Full-Text [PDF 247 kb]   (157 Downloads)    
Type of Study: Original Article | Subject: Neurology
Received: 2021/07/15 | Accepted: 2021/11/16 | Published: 2022/06/1
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Daneshyar S, Ghiasian M, Moradi S, Khanlarzadeh E. Efficacy of levetiracetam, lamotrigine and sodium valproate on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy: A double blind randomized clinical trial. Caspian J Intern Med. 2022; 13 (3) :617-622
URL: http://caspjim.com/article-1-3007-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 3 (Summer 2022) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4419